SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Mahalia Jackson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMahalia Jackson
Date of birth1911-10-26
IdentifiersMRN HR-ML035-SYN-TD; SSN (made up) 000-35-4692
Document date1964-05-11
AuthorBeatrice Fontenot, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review after nine weeks of treatment. [S]

History of Present Illness

Ms. Jackson returns nine weeks after starting prednisone and methotrexate. The electrophysiology study induced sustained ventricular tachycardia, and a dual-chamber defibrillator was placed the next day; the wound has healed and she has had no shocks. The remote transmission last week showed two short runs of ventricular tachycardia in March and none since. She climbs two flights before stopping, the cough has gone, and the palpitations are rare. She has had a large appetite, gained weight, and sleeps poorly on prednisone. Home glucose readings are 100 to 130 mg/dL. She has had no mouth sores, nausea or infections on methotrexate, and drinks no alcohol. The final EBUS cultures were negative. No methotrexate blood tests have been done since she started. She is eager to sing again and has concerts offered from the end of May. She has had no thoughts of self-harm. [S]

ElementDetail
DeviceDual-chamber defibrillator since the electrophysiology study; no shocks; two runs of ventricular tachycardia in March, none since
SymptomsTwo flights of stairs; cough gone; palpitations rare
Steroid effectsLarge appetite, weight up 2.8 kg, poor sleep; home glucose 100 to 130 mg/dL
Methotrexate15 mg weekly; no mouth sores or nausea; no blood tests since starting
WorkConcerts offered from the end of May

Review of Systems

SystemResultFinding
ConstitutionalPositiveLarge appetite; weight 94.0 kg; no fever
RespiratoryNegativeCough gone; breathless only on the second flight
CardiovascularNegativePalpitations rare; no shocks, fainting or ankle swelling
Ears, nose, mouth, and throatNegativeNo mouth sores or thrush; voice strong
EndocrinePositiveHome glucose 100 to 130 mg/dL; no thirst
PsychiatricPositivePoor sleep on prednisone; mood good; PHQ-9 5; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning40 mg each morningOral route1964-03-09 to 1964-05-11completedS
Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks30 mg each morning for four weeksOral route1964-05-11 to 1964-06-08completedS
Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays15 mg once weeklyOral route1964-03-09 to 1964-05-11completedS
Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays20 mg once weeklyOral route1964-05-11activeS
Folic acid 1 mg oral tablet, one tablet by mouth dailyOne tablet dailyOral route1964-03-09activeS
Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food1500 mg once daily with foodOral route1964-03-09 to 1964-07-06completedS
Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutesOne tablet once weeklyOral route1964-03-16activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet dailyOral route1964-03-09activeS
Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth dailyOne tablet dailyOral route1964-05-11activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1964-05-11Body height170cmS
1964-05-11Body weight94kgS
1964-05-11Body mass index (BMI) [Ratio]32.5kg/m2S
1964-05-11Systolic blood pressure138mm[Hg]S
1964-05-11Diastolic blood pressure86mm[Hg]S
1964-05-11Heart rate66/minS
1964-05-11Respiratory rate16/minS
1964-05-11Body temperature36.6CelS
1964-05-11Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1964-05-11Hemoglobin [Mass/volume] in Blood13.1g/dL12-15.5 g/dLNormalS
1964-05-11Leukocytes [#/volume] in Blood by Automated count9.810*3/uL4-11 10*3/uLNormalS
1964-05-11Lymphocytes [#/volume] in Blood by Automated count1.210*3/uL1-4.8 10*3/uLNormalS
1964-05-11Platelets [#/volume] in Blood by Automated count26210*3/uL150-400 10*3/uLNormalS
1964-05-11Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1964-05-11Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
1964-05-11Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.59-1.04 mg/dLNormalS
1964-05-11Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M75mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1964-05-11Glucose [Mass/volume] in Serum or Plasma118mg/dL70-99 mg/dLHighS
1964-05-11Calcium [Mass/volume] in Serum or Plasma9.6mg/dL8.6-10.3 mg/dLNormalS
1964-05-11Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-35 U/LNormalS
1964-05-11Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L8-35 U/LNormalS
1964-05-11Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma96U/L35-104 U/LNormalS
1964-05-11Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
1964-05-11Hemoglobin A1c/Hemoglobin.total in Blood6.3%Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetesHighS
1964-05-1125-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mL30-100 ng/mLLowS
1964-05-11Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma140pg/mL<=125 pg/mLHighS
1964-05-11FVC measured/predicted84%>=80%NormalS
1964-05-11FEV1 measured/predicted85%>=80%NormalS
1964-05-11FEV1/FVC80%>=70%NormalS
1964-05-11Diffusion capacity.carbon monoxide/Predicted70%>=80%LowS
1964-05-11Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S

Physical Exam

Vital signs recorded on 1964-05-11; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 94.0 kg; blood pressure 138/86, pulse 66 and regular
RespiratoryClear to auscultation
CardiovascularRegular rhythm; no murmur; defibrillator pocket healed without swelling or tenderness
MouthNo thrush or ulcers
SkinMild facial fullness; no bruising or infection
PsychiatricCheerful, impatient to sing

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excludedresolvedconfirmed R06.09S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation.
Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked forresolvedconfirmed R00.2S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed.
Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raisedresolvedconfirmed E83.52S — Synthetic finding; resolved on treatment.
Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosisactiveconfirmed D86.2S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable).
Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heartactiveconfirmed D86.85S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R.
Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manageactiveconfirmed Z79.52S — Synthetic treatment status.
Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoringactiveconfirmed Z95.810S — Synthetic device status after the synthetic implant.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingSpirometry and diffusing capacity (FVC, FEV1, FEV1/FVC, DLCO)At diagnosis, three months after starting treatment, then every three to six months while treatment changesCompleted todayFVC 84 percent, FEV1 85 percent, FEV1/FVC 80 percent, DLCO 70 percent of predicted
LaboratoryMethotrexate safety: blood count, liver tests and creatinineBefore starting; every two to four weeks for the first three months; then every eight to twelve weeksDeferredA deviation: the blood count, liver tests and creatinine due two to four weeks after methotrexate began were not done, because no laboratory order was placed for the long gap between visits. No harm resulted: today hemoglobin 13.1 g/dL, white cells 9.8 (raised by prednisone), lymphocytes 1.2, platelets 262, ALT 31, AST 28, alkaline phosphatase 96 U/L, albumin 4.1 g/dL, creatinine 0.92 mg/dL and eGFR 75 are normal. Corrective action: standing orders every four weeks until twelve weeks and then every eight to twelve weeks, at a laboratory near home or on tour, with a reminder to her and to the clinic
LaboratorySerum calciumAt diagnosis, then at each treatment visit while it was raised or vitamin D is givenCompleted today9.6 mg/dL, normal
LaboratoryElectrolytesAt each visit on glucocorticoidsCompleted todaySodium 139, potassium 3.9 mmol/L
Laboratory25-hydroxyvitamin DBefore replacement and after it startsCompleted today24 ng/mL; replacement started now that calcium is normal
LaboratoryGlucose and A1c on glucocorticoidsAt each visit; A1c every three monthsCompleted todayGlucose 118 mg/dL; A1c 6.3%
LaboratoryNT-proBNPAt each cardiac reviewCompleted today140 pg/mL
ExaminationBlood pressure and weight on glucocorticoidsEach visitCompleted today138/86 mmHg; weight 94.0 kg, up 2.8 kg
ImagingBone density (DXA) and FRAXAt the start of long-term glucocorticoids, then every one to three yearsUp to dateMarch: femoral neck T-score -1.6; moderate risk; alendronate
ExaminationDefibrillator check (remote and in clinic)Remote transmissions monthly and with any symptom; clinic check every three to six monthsCompleted todayRemote transmission last week: two runs of nonsustained ventricular tachycardia in March, none since; no therapies; normal lead values
LaboratoryExclusion of other granulomatous causesAt diagnosisUp to dateFinal mycobacterial and fungal cultures negative at eight weeks
Medication safetyPneumocystis prophylaxisWhile prednisone is 20 mg or more with a second immunosuppressantCompleted todayAtovaquone continues until prednisone falls below 20 mg
Medication safetyVaccination on immunosuppressionPer scheduleCompleted todayHepatitis B dose 2 given today, completing the two-dose series; zoster dose 2 due in August
SurveyDepression screen (PHQ-9)At diagnosis and at each phase of treatmentCompleted todayPHQ-9 5
Self-managementPerforming and travel planAt each visitCompleted todayTwo concerts a week in the United States from the end of May, with a rest day after each; no international touring until after the August PET; voice care; travel letter and device card

Goal progress:

Immunizations given today: Hepatitis B vaccine (adjuvanted, two-dose series), dose 2 [S]

Guideline basis: Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022); Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Methotrexate blood tests every four weeks. Remote device checks monthly. Review in mid-August after the repeat FDG-PET, echocardiogram and lung function. Call for fever, cough, breathlessness, a shock, or fainting. Next scheduled visit 1964-08-24: six months of treatment: repeat FDG-PET, steroid taper, and plans for touring. [S]